Synthetic oligodeoxynucleotides (ODNs) had been employed in gene modification and represent an alternative approach to 'cure' genetic disorders caused by mutations. To test the ability of ODN-mediated gene repair in bone marrow-derived mesenchymal stem cells (MSCs), we established MSCs cell lines with stably integrated mutant neomycin resistance and enhanced green fluorescent protein reporter genes. The established cultures showed morphologically homogenous population with phenotypic and functional features of mesenchymal progenitors. Transfection with gene-specific ODNs successfully repaired targeted cells resulting in the expression of functional proteins at relatively high frequency approaching 0.2%. Direct DNA sequencing confirmed that phenotype change resulted from the designated nucleotide correction at the target site. The position of the mismatchforming nucleotide was shown to be important structural feature for ODN repair activity. The genetically corrected MSCs were healthy and maintained an undifferentiated state. Furthermore, the genetically modified MSCs were able to engraft into many tissues of unconditioned transgenic mice making them an attractive therapeutic tool in a wide range of clinical applications.
Introduction
Advances in stem cell research have raised the possibility of using adult stem cells from bone marrow for treatment of inherited and acquired diseases. Bone marrow contains mesenchymal progenitor cells, called mesenchymal stem cells (MSCs) that have the capacity to differentiate into a variety of unique mesenchymal tissues including bone, cartilage, muscle, fat, tendon, marrow stroma and other connective tissues. [1] [2] [3] [4] [5] The multipotential of MSCs, their relatively easy isolation, culture and ex vivo expansive potential have attracted considerable attention in efforts to develop cell and gene therapies and have made these cells an attractive therapeutic tool in a wide range of clinical applications. 6 During the past decade many different viral vectors including retrovirus, 7 adenovirus, [8] [9] [10] [11] [12] [13] lentivirus [13] [14] [15] [16] and adeno-associated virus 13, [17] [18] [19] [20] have been utilized to deliver genes to or modify genes in MSCs. Although the viral gene delivery to MSCs has made an impressive advancement toward clinical applications, 21 several drawbacks exist. The retroviral transfer requires cell division for infection, thereby limiting infections of slowly cycling stem cells. 21 Moreover, several studies have documented gradual inactivation of transferred gene expression driven by the viral promoter, even though the vector DNA clearly remains present. 22 Also, there are a safety concerns related to a possible generation of replication-competent retrovirus and random integration of virus that could activate an oncogene or inactivate a tumor suppressor gene. 23, 24 Adenoviral delivery system has advantages since it does not require the target cell division for infection and high-titer virus can be generated. 24 However, adenoviral vectors are likely to infect nonreplicating, terminally differentiated cells, thus limiting expression of the transit times of these cells. Moreover, infected cells could become targets for the immune system and eliminated from the body. 24 In addition, high-titer adenovirus used for clinical situations caused acute immune response and toxicity of the host. Nonviral gene delivery systems seem to be offering the advantage of relative simplicity of preparation, avoidance of the size constraints of viral packaging, reduced toxicity and immunogenicity, and a generally advantageous safety profile. 13, [25] [26] [27] [28] [29] [30] The main problem of nonviral gene approach, however, is the relatively low and transient expression of the transferred gene. On the other hand, conventional plasmid-based eukaryotic expression vectors do not replicate and therefore are not retained in the nucleus of the rapidly dividing cells, and as a consequence the plasmid DNA is rapidly diluted. Furthermore, loss of plasmid DNA may also be unavoidable even in nondividing cells due to lack of nuclear matrix retention, and subsequent degradation and loss through the nuclear envelope.
In spite of the large number of reports to introduce genes in need into MSCs by viral transduction, a strategy to 'cure' a genetic defect by correcting the gene at the site of the mutation has not yet been attempted. Oligonucleotide-directed gene repair represents an alternative approach to genetically manipulating MSCs for therapeutic purposes. We developed an experimental system utilizing relatively short single-stranded oligodeoxynucleotides (ODNs) that allow direct site-specific correction of mutations in endogenous genes. 31 Several characteristics of the ODNs make them an attractive tool for in vivo applications. The primary advantage of such an approach is the ability to make a permanent specific alteration into a gene of interest in a single step, without disturbing the genomic organization required for endogenous expression and regulation of the targeted gene. In the past 8 years, we have made significant progress in our understanding of the mechanism responsible for gene alteration by ODNs [32] [33] [34] [35] [36] and provided clear evidence that this approach can be used to introduce permanent site-specific changes into episomal and chromosomal DNA of somatic cells 31, 37, 38 and embryonic stem (ES) cells. 39, 40 The goal of the present study was to assess the use of ODN-directed gene repair in MSCs. To achieve this goal, first, we developed the procedure for isolation of adult murine MSCs and demonstrated that established cultures represent morphologically homogenous population of cells with phenotypic and functional features of mesenchymal progenitors. Second, our data show that relatively short ODNs, 45 bases homologous to the target sequence except for a single mismatch to the targeted base, can create sequence-specific, homology lengthdependent and strand-specific gene alterations permanently in the genomic DNA of mouse MSCs at a relatively high frequency. Furthermore, we showed that the genetically modified MSCs maintain an undifferentiated state and are able to engraft into many tissues of unconditioned transgenic mice making them an attractive therapeutic tool in a wide range of clinical applications.
Results

Isolation and characterization of mouse bone marrow-derived MSCs
We developed a novel method for the isolation of MSCs from mouse bone marrow, based on negative immunodepletion using a cocktail of biotin-labeled lineagespecific antibodies and magnetic cell sorting. The original cultures of mouse adult MSCs were produced from wild-type C57BL6 and mutant CUBeGFP/Y66S transgenic mice, as described in 'Materials and Methods'. Routinely, B1 Â 10 6 MSCs were produced from each mouse after lysis of red blood cells followed by negative selective depletion of mature hematopoietic cells, such as T cells, B cells, monocytes/macrophages, granulocytes, erythrocytes and their committed precursors from bone marrow. The MSCs appeared initially as adherent, spindle-shaped cells after 3-4 days of culture. Then, the cells grew rapidly, and could be easily expanded. Several clones (n ¼ 5) from each mouse strain were picked and propagated for further analyses. Established cell lines were designated as wtMSC and MSC-EGFP À , respectively.
To determine the antigen expression profile of the isolated MSCs, immunophenotypic analysis (fluorescence-activated cell sorting, FACS) using fluorescently labeled antibodies against a panel of several surface markers including CD45, CD11b, CD31, CD44, Ly-6A/E (SCA-1), CD71 and CD90.1 (Thy-1.1) was performed (Figures 1a and b) . As expected, more than 99% of cells in all tested clones were strongly stained by antibodies directed against Sca-1, which is a hallmark of various types of stem cells, including hematopoietic, MSC/ progenitor, epithelial and myoendothelial cells. Also, cells were positive for CD44 (491%), which mediates cell attachment to hyaluronan and osteopontin, and CD29 (479%), which represents the receptor for extracellular matrix (ECM). In contrast, the cells were negative for the hematopoietic cell marker CD45 as well as CD31, CD90.1 and CD11b, which are markers for granulocytes, monocytes, natural killer cells and macrophages.
The most prominent characteristic of MSCs is their capacity to differentiate into multiple cell types. To verify the multipotential of the generated wtMSC and MSC-EGFP À cultures in vitro, the cells were analyzed for osteogenic, adipogenic and chondrogenic potentials. To induce osteogenic differentiation, the cells were maintained in differentiation basal osteogenic medium for up to 3 weeks. Cell cultures were morphologically examined and alkaline phosphatase (ALP) activity and ECM calcification were assessed. As expected, the cells underwent a dramatic change in cellular morphology from spindle-shaped to cuboidal. In addition, histochemical analysis of the cells for ALP activity showed a high and uniform staining (Figure 2a ). When the cultures were examined for their ability to elaborate a mineralized ECM, a substantial calcium deposition was detected, while no calcium deposition was seen in control MSC cultures (data not shown). To verify these data, mRNA expression of the osteogenic markers such as ALP, core-binding factor a1 (Cbfa1) and osteocalcin (OCN) was also investigated. As expected, cells under differentiation conditions showed expression of the indicated osteogenic marker genes (data not shown). Although a low-level expression could be detected in control nondifferentiated cultures, differentiated wtMSC and MSC-EGFP À cells displayed a much higher level of osteogenic markers (data not shown).
To induce adipocytic differentiation, cells were maintained in adipogenic induction medium for 2 weeks. For histochemical examination, adipogenic cultures were stained for the presence of intracellular lipid droplets as an indicator of intracellular lipid accumulation. Oil red O staining of 2-week cultures for intercellular lipid vacuoles did not show any cells resembling adipocytes in control cultures, whereas upon treatment with adipogenic inductive medium, cells with a typical adipocyte phenotype containing intracellular lipid droplets appeared (Figure 2b ). Moreover, reverse transcription (RT)-PCR analysis showed adipocyte-related transcripts, such as lipoprotein lipase (LPL) and peroxisome proliferator-activated receptor g2 (PPARg2), in differentiated wtMSC and MSC-EGFP À cells (data not shown).
Chondrogenic differentiation was performed using the micromass culture technique in which cellular condensation (a critical first event of chondrogenesis) is duplicated. Chondrogenic medium was gently overlaid so as not to detach the cell nodules and cultures were maintained for up to 3 weeks. Under these conditions, the cells formed nodules associated with a well-organized ECM rich in sulfated proteoglycans as detected using Alcian blue staining under acidic conditions (data not shown). Nodules were associated with an Alcian blue-positive ECM, indicative of the presence of sulfated proteoglycans within the matrix, whereas no obvious staining was observed in undifferentiated control MSCs cultures. Next, cell aggregates were analyzed by RT-PCR using specific primers for chondrogenic-related genes. As expected, differentiated aggregated cultures showed a marked induction of mRNAs from chondrogenic genes Sox9 and Acan (data not shown). In addition, expression of ColII and ColIX mRNA was increased progressively. Overall, our data indicate that generated MSCs lines display phenotypic features of adult MSCs and possess Gene modification by ODNs in MSCs K Flagler et al the capacity to differentiate toward specific lineages when exposed to the appropriate inductive media.
Chromosomal gene repair in mouse MSCs
To investigate the feasibility of ODN-based gene targeting at the chromosomal level in MSCs, we generated two stable cell lines with integrated mutant reporter genes. The first system is based on the neomycin phosphotransferase II (neo) gene of transposon Tn5 that encodes a protein of 264 amino acids and inactivates antibiotics by catalyzing the transfer of the terminal phosphate of ATP to the drug. To create an inactive mutant version of the neo gene (neo s ), a mutation was introduced into codon 22 (Y22X), which creates stop codon and completely inactivates the neo gene. The mutant codon can be corrected from TAG to TAT leading to restoration of phosphotransferase activity (Figure 3a) . The advantage of this system is that when the cells containing the mutant reporter gene are corrected, they can be detected by selection of cells resistant to G418, thus, providing a To make an MSC line with stably integrated puromycin-resistant neomycin-susceptible cassette, wtMSCs were stably transfected with pNeoS1Pur plasmid using Amaxa nucleofection followed by puromycin selection. Resistant colonies were individually picked and expanded into distinct clonal lines of neomycin-susceptible cells. Integration of the reporter cassette was verified by RT-PCR with gene-specific primers (Table 1) and Southern blot analyses using the full-length neo gene cDNA as a probe (Figure 4a) To provide more than one system for testing, we established a second MSC line from CUBeGFP/Y66S transgenic mice, which is based on the enhanced version of green fluorescent protein (EGFP). Since EGFP autofluorescence, it renders itself as an easily detectable marker. In transgenic mice, mutation Y66S in the EGFP chromophore ( Figure 3b ) produced no detectable fluorescence, as determined by both microscopy and FACS analysis. 41 The advantage of this system is that when the cells containing mutant reporter gene are corrected, the activity of the mutant EGFP is restored and the corrected cells can be visualized by fluorescence microscopy, also providing straightforward assays for assessment of ODN-mediated gene correction activity. The Y66S mutant version of EGFP was symbolized EGFP À . To confirm the presence and expression of mutant EGFP in the established MSC-EGFP À line, Southern blot, RT-PCR analysis and western blot analysis using EGFP-specific monoclonal antibodies, which recognize both the wildtype and mutant proteins, were performed ( Figure 4b ). For systemic studies, we selected the clone, which expressed the highest level of mutant protein.
As a first step toward ODN-mediated gene targeting, the delivery of ODN into MSCs was optimized by monitoring an accumulation of the nuclear fluorescence in established MSC lines. Fluorescent-conjugated ODN was complexed with three different liposome reagents as described in 'Materials and Methods'. Six hours after transfection, the cellular uptake and localization of fluorescein isothiocyanate (FITC)-ODN in individual cells was monitored by using fluorescence confocal microscopy. As shown in Figure 5 , fluorescent oligodeoxynucleotides (FITC-ODN) accumulation and distribution were highly dependent on delivery agent. A massive nuclear internalization (B90% nuclei positive) was observed when FITC-ODN was delivered by Super- . However, in spite of the fact that SuperFect showed superb nuclear delivery, this agent was excluded from experimentation due to its high toxicity on MSCs (data not shown). Based on these data, Lipofectamine 2000 was used throughout the study.
A series of ODNs were synthesized to test their activity in gene correction in established cell lines. In all cases, chromosomal targeting was performed using ODNs in antisense orientation with a 45 nt homology to the targeted chromosomal sequence in accordance with original structure ( Figure 3) . As a control, we used ODN fully complementary to the mutant sequence. 
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K Flagler et al 48 h after transfection with Neo-ODN and continued until neomycin-resistant colonies appeared and grew large enough to be picked (usually 10-14 days) and then propagated for further analysis. The MSC-EGFP À cells transfected with ODN designed to restore EGFP function were examined for expression of EGFP using fluorescence microscopy or subjected to live sorting to enrich the EGFP + fraction. In each case, the efficiency of gene correction was determined from at least five independent experiments as a proportion of cells with the corrected phenotype divided by the total number of cells used for analysis.
As presented in Table 2 , the ODNs with the centrally located mismatch-forming nucleotide, Neo-1 and EGFP-1, were able to produce relatively high levels of gene modification in both cell lines regardless of the targeted gene. Interestingly, the gene correction rate was higher in MSC-Puro r /Neo s than in MSC-EGFP À cells. These differences could be attributed in part to the survival ability of wild-type EGFP-expressing cells due to toxic effect of EGFP and are discussed later. When ODNs with shifted mismatch were used, mismatch close to the 5 0 -end was found to be more disruptive for ODN activity than those of 3 0 -end. In all cases, the correction frequency decreased remarkably when the mismatch-forming nucleotide was moved from the middle of the ODN toward the 5 0 terminus. On the contrary, the activity of the ODN was less affected when adjusting the position of the mismatch-forming nucleotide toward the 3 0 terminus (9 nt) except for the very end of the 3 0 -end (4 nt). In fact, the frequency of gene repair decreased when the mismatched nucleotide was placed 9 nt from 3 0 -end. To validate the DNA sequences of phenotypically corrected cells, and assess their multipotency, transfections with modifying ODNs were performed as described above and cells were subjected for selection (Neo r ) or live sorting to enrich the fraction of EGFPpositive cells. To obtain a sufficient number of EGFP-corrected cells, the number of initially targeted MSC-EGFP À cells was increased up to 5-7 Â 10 5 per transfection. With these conditions, we were able to isolate approximately 900 EGFP-positive cells out of 1 Â 10 6 totally sorted cells. Immediately after sorting, EGFP-positive cells were seeded into two 10 cm dishes and MSC-EGFP + cells, the region surrounding the point mutation was amplified and subsequently sequenced using direct gene-specific primers. All examined clones exhibited a correction of TAG codon to TAT at position 22 for the Neo gene and TCC codon to TAC codon at position 66 for the EGFP gene (Figures 6a and b) . Among 10 clones for each cell line, no other DNA sequence changes were observed in the amplified region that flanked the corrected base confirming the site-specific manner of gene correction. Moreover, the genetically corrected cells exhibited multiple differentiation capacity when cultures were exposed to adipocyte, osteoblast and chondrocyte differentiation conditions as described above (data not shown). The data presented here show that modified ODNs can create specific alterations in the genomic DNA of mouse MSCs at frequencies approaching 0.2%, and that the genetically corrected cells maintain an undifferentiated state.
Transplantation of genetically corrected MSC-EGFP+ cells into CUBeGFP/Y66S transgenic mice
The CUBeGFP/Y66S transgenic mice offer an excellent opportunity to test whether genetically corrected MSCs could be used for the in vivo therapeutic applications. (Figure 7a ). Immediately after labeling, the cells were injected into the lateral tail vein of transgenic mice. Transplanted animals were monitored daily and did not show any distress or behavioral changes throughout the study.
Three weeks after transplantation, the mice were killed and the heart, kidney, lung, liver, spleen, muscle, skin and blood were histologically examined for the presence of transplanted cells using fluorescent microscopy. Because essentially all transplanted cells are FM-DiI-EGFP positive, the FM-DiI fluorescence plus the expression of wild-type EGFP protein provided an effective means of tracking transplanted cells in the mouse body and avoiding potential artifacts due to unspecific autofluorescence. As presented in Figure 7 , all (Figures 7b-e) . In many cases, transplanted cells showed morphological similarities to the cells of the resident organs. The lungs and spleen contained more numerous distributions of engrafted cells. Scattered cells were also present in the muscle tissue, heart and skin but at very low numbers (data not shown). These data indicate that organs harboring the highest number of engrafted cells are presumably primary targets for bone marrowderived MSCs. But, longer posttransplantation period may be required for better engraftment and repopulation of MSC in organ-specific environment.
We also examined local transplantation of FM-DiI-MSC-EGFP + cells into skin. Skin is an ideal organ where MSCs can be administered locally and cell engraftment can be easily monitored in the treated site. For direct transplantation, cultured FM-DiI-MSC-EGFP + cells (5 Â 10 5 per mouse) were injected intradermally into dorsal skin closest to dermal-epidermal junction. The efficiency of the injection was assessed 3 weeks after transplantation. Fluorescent microscopy of skin sections showed persistent FM-DiI-MSC-EGFP + -positive cells in the dermis with no extensions into the epidermis (Figure 7f) . Moreover, the majority of transplanted cells were closely associated with interfolicular dermis.
Discussion
Recent advances in studying bone marrow-derived stem cells have shown that this cell population exhibits a number of properties that suggest the feasibility of their use as a therapeutic vehicle. These include relatively simple isolation procedures; the ability to be cultured in vitro in minimal conditions and to expand to quantities required for therapy; the ability for ex vivo manipulation; plasticity, the potential to differentiate under exogenous stimuli and the ability to engraft after systematic or local reintroduction.
In the present study, we developed the procedure for isolation of adult murine bone marrow-derived MSCs and demonstrated that established cultures represent morphologically homogenous population of cells with phenotypic and functional features of mesenchymal progenitors. The developed procedure proved to be a novel and reliable approach to prepare a homogeneous fraction of murine MSCs. Moreover, we showed for the first time that modified ODNs can create sequencespecific, permanent alterations in the genomic DNA of mouse MSCs at relatively high frequency. The genetically corrected MSCs are healthy and maintain an undifferentiated state. Furthermore, the genetically modified cells are able to engraft into many tissues of unconditioned transgenic mice making them an attractive therapeutic tool in a wide range of clinical applications.
The current procedures for isolation of bone marrowderived MSCs mostly rely on selective adherence of crude bone marrow suspension to the substrate of culture vessels. Usually, such initial cultures show a heterogeneous population of cells often contaminated with cells from hematopoietic lineage as well as monocytes and macrophages requiring prolonged cultivation to obtain a homogenous population of MSCs. Here, we present a procedure allowing reliable isolation of a homogenous fraction of MSCs from mouse bone marrow based on negative immunodepletion using the biotinlabeled cocktail of lineage-specific antibodies followed by a magnetic cell sorting. Using such approach, we were able to obtain a highly enriched population of mouse MSCs that were completely devoid of hematopoietic cell contamination as shown by immunophenotypic analysis (FACS). Considerable progress has been made toward characterizing the cell surface antigenic profile of bone marrow-derived MSCs populations. Based on the current data, MSCs are thought to be negative for hematopoietic surface markers such as CD34, CD45, CD14, CD31, CD133 and positive for CD105, CD166, CD54, CD55, CD13 and CD44 (11) (12) (13) (14) (15) (16) (17) (18) . 1, 3, 42 Despite the fact that no perspective markers exclusively defining MSC are currently available, there is also general agreement that MSCs lack typical hematopoietic antigens, such as CD45, CD34 and CD14.
One of the defining characteristics of MSCs is their self-renewal potential and ability to differentiate into several cell types in vitro depending on culture conditions. The mouse MSC cultures established in this study exhibited multilineage potentials in vitro differentiating toward adipogenic, osteogenic and chondrogenic lineages when cultured in the presence of lineagespecific differentiation factors as determined by their morphology and gene expression analyses. When cells were cultured with osteogenic medium, a distinct osteoblastic phenotype was observed, as evidenced by induction of ALP mRNA expression and activity, and subsequent matrix mineralization. Cultures maintained in adipogenic medium gave rise to adipocytic cells containing intracellular lipid droplets and expressing transcripts of adipogenic genes such as LPL and PPARg2, the latter a characteristic of committed adipocytes. 43 Chondrogenic differentiation of cell aggregate cultures resulted in appearance of chondrocyte-like cells and deposition of sulfated proteoglycans, indicating the formation of cartilage-like ECM. Moreover, the mRNA expression of Sox9, a key transcription factor in chondrocyte differentiation, 44 was markedly upregulated in cell aggregates. These results are consistent with those observed for MSCs isolated from a variety of different species including human, 42 canine, 45 rat, 46 cassette showed that all generated clones were capable of undergoing differentiation which is highly indicative of the pluripotent, progenitor characteristics of generated stable lines.
Efficient delivery of ODN into cells is a crucial step for successful targeting. In recent years a series of highly effective cationic liposome agents have been developed. However, the efficiency of liposomes appears to be dependent on many variables: cell type, lipid membrane composition, relative ratio of the lipid to ODN, endocytosis of ODN, release from endosome, nuclear transfer and the stability of the ODN-lipid complex during theses processes. On the basis of our experience, it has been difficult to deliver ODN by liposome to the majority of primary cell cultures. In contrast, we have been able to achieve consistently high efficiency of nuclear ODN uptake in MSCs using SuperFect and Lipofectamine 2000 agents. The mechanism of this efficient delivery is not yet fully elucidated. The use of positively charged liposomes might reduce the negative charges of the DNA molecule facilitating its delivery through the cell membrane. Also, DNA can induce cationic liposome fusion, perhaps by bridging two liposomes, drawing them closer and destabilizing the bilayer. This fusogenic property provides opportunity for the DNA to enter the new liposome or to associate with the net negative charge on a cell membrane to deliver their DNA.
Our results demonstrate that ODN-mediated gene repair of chromosomally integrated mutant neomycin resistance and EGFP genes in MSCs occurs with relatively high frequency ranging from 10 À4 to 10 À3 consistent with our previous data. 35 In addition, structural modifications, such as shift of mismatch-forming nucleotide from a central position toward to the 3 0 -and 5 0 -ends of ODN had a more negative effect on correction activity of ODN. In fact, the mismatch-forming nucleotide close to the 5 0 -end was much more disruptive than its 3 0 -counterpart suggesting that the initial pairing of the 5 0 -region of ODN with its complementary target might be a crucial step during the strand invasion process. 34, 35 It is interesting to note that not all corrected cells were able to survive and in fact, the only one-third of EGFP + sorted cell produced viable clones. Recently, Olsen et al. 49 found that the majority of corrected CHO-K1 cells were arrested at G 2 /M stage and only 2% of the initially EGFPcorrected cells made viable colonies. The authors concluded that targeted sequence alteration by ODN by itself is somehow arresting mitosis of the corrected cells, suggesting difficulties in expansion of corrected cells. However, we believe that cautions are needed in generalization of these experiments: (1) clonal expansion of the EGFP-corrected cells is dependent on the cell types since the other group reported that 60% of EGFPcorrected 293T cells were expandable and clonable 50 and somewhat in agreement with our finding; (2) the copy number of the integrated reporter gene used for clonal analysis by Olsen et al. ranged 30-60 copies of mutant EGFP, much higher than normal endogenous gene; (3) variable toxicity of EGFP has been reported in many cell types. 51 Our previous experiments also support the notion that the clonal expansion of corrected cells varies according to the targeted gene and cell types. Using clonal analysis, we demonstrated that an ODN corrected a point mutation in the endogenous tyrosinase gene, resulting in an inheritable restoration of enzymatic activity, melanin synthesis and pigmentation changes in albino melanocytes. 37 We were able to clone more than 60% of these pigmented cells. Our clonal experiments in ES cells also showed that the number of LacZ-corrected cells at 48 h after transfection (1 out of 5 Â 10 4 ) was similar to the number of viable LacZ-positive colonies obtained by limiting dilution meaning that most of the mutant LacZ-corrected ES cells expanded to make viable colonies. 39 Very recently, we showed that targeting ESNeo s cells with a correcting ODN resulted in about 50-100 Neo r clones from the initial 1 Â 10 6 ES cells. 40 Detection of EGFP fluorescence, a priori, requires that correction has taken place and been completed so that transcription and translation of the corrected gene product were detectable. Then, how is it possible that a correction event has been completed but somehow left its signatures so that the majority of cells cannot go through mitosis? Even a partial correction, for example a persisting mismatch, would not be sufficient to arrest the cell cycle, since it will be repaired in the next cycle by postreplication mismatch repair mechanisms. A more logical interpretation of these results would be that a small number of cells exist that are poised to escape cellular DNA damage surveillance and these cells have a higher probability of successful gene repair. The repair event has marked these cells to be fluorescent (for example, correction of mutant EGFP) so that they are tractable. The persistent presence of a large amount of ODNs in these cells might trigger repetitive DNA repair events that eventually lead to the apoptosis of ODN -repair-competent cells. This situation might be quite analogous to the apoptosis of MMR-competent cells that is triggered by the repetitive but failed repair of a DNA lesion containing methylated bases, such as O 6 -methylguanine. 52 As a consequence, MMR-competent cells are 100-fold more sensitive to killing by methylating agents than MMR-deficient cells.
Our data indicate that the genetically corrected MSCPuro r /Neo r and MSC-EGFP + cells continue to retain their normal phenotype without decline in growth rate or ability to differentiate into mesenchymal lineages suggesting their potential use in vivo. Transplantation of genetically corrected MSC-EGFP + cells into unconditioned CUBeGFP/Y66S transgenic mice resulted in widespread distribution of donor cells into multiple organs including bone marrow, lungs, liver, kidney, spleen, and transplanted cells were able to persist up to 4 weeks and maintain transgene expression. The high incidence of MSC-EGFP + cells in the mouse body after extended postinfusion period suggests that subsequent to their homing in the bone morrow, mesenchymal progenitors are able to migrate into distinctive mesenchymal and nonmesenchymal tissues. Our data are in good agreement with previously published reports demonstrating that after syngeneic or xenogeneic transplantation of MSCs derived from the bone morrow of mouse, rat or nonhuman primates, donor cells engraft into many tissues of conditioned recipients. [53] [54] [55] [56] [57] It is still unclear whether transplanted cells continue to retain their multilineage potentials and clonogenic ability or if they were able to commit into residing tissue. At present, Overall, our results provide evidence supporting the suitability of genetically corrected MSCs by ODN in cellbased therapeutic applications. Therefore, these data suggest that unconditioned transplantation of genetically altered MSCs may represent an alternative for providing cellular therapy to avoid the complications associated with cytotoxic conditioning.
Materials and methods
Synthesis and purification of oligonucleotides
45-mer oligonucleotides were synthesized and purchased from Operon Biotechnologies Inc. (Huntsville, AL, USA). FITC-ODNs were synthesized by incorporating fluorescein phosphoramidite at the 5 0 -end, as described previously. 33 All oligonucleotides were synthesized using 10 mmol scale and purified by high-pressure liquid chromatography. To protect oligonucleotides from nuclease degradation, four 2 0 -O-methyl RNA residues were incorporated at each end of oligonucleotide as described previously. 31 
Plasmids
A plasmid containing puromycin-resistant and neomycin-sensitive genes (pNeoS1Pur) was constructed by cloning the puromycin cassette from pPur vector (Clontech, Mountain View, CA, USA) into multiple cloning site of pcDNA3.1+ vector (Invitrogen, Carlsbad, CA, USA) as described previously. 40 The site-directed mutagenesis (Stratagene, La Jolla, CA, USA) was used to mutate the 22nd codon of the neomycin resistance gene from TAT to TAG. The pCUB-EGFP66 plasmid encoding mutant EGFP gene 41 was kingly provided by Dr JF Engelhardt (University of Iowa, Iowa City, IA, USA). All plasmid DNAs were prepared using a large-scale isolation protocol (Qiagen, Santa Clara, CA, USA).
Mouse strains
C57BL6 mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Homozygous transgenic mice expressing the CUBeGFP/Y66S transgene were also kindly provided by Dr JF Engelhardt. All animals were housed under sterile conditions in microisolator cages in the animal facility of Thomas Jefferson University under approved protocols.
Isolation of MSCs from mice and tissue culture conditions
To isolate MSCs from the crude bone marrow, 3-to 6-week-old wild-type C57BL6 or homozygous mutant EGFP (CUBeGFP/Y66S) mice were euthanized by CO 2 inhalation. Their femurs and tibiae were carefully cleaned of adherent muscles and connective soft tissues, the epiphyses were removed with a rongeur, and marrow was harvested by inserting a syringe needle (20-gauge) into one end of bone and flushing with Dulbecco's modified Eagle's medium cell culture media (Invitrogen). After being drawn and expelled from the same syringe three times to dispense the marrow, cells were collected by centrifugation. To obtain single-cell suspension, the collected bone marrow was applied to a 30 mm mesh separation filter (Miltenyi Biotec, Bergisch Gladbach, Germany) and the resulting pellet was resuspended with a MidiMACS phosphate-buffered saline (PBS) containing 2 mM EDTA, 0.5% bovine serum albumin. Then, a red blood cell lysis solution (0.8% NH 4 Cl, 0.1 mM EDTA, in dH 2 O) was added, at ratio 9:1, and incubated on ice for 10 min. The suspension was centrifuged and the cell pellet was resuspended in the MidiMACS buffer. To remove the hematopoietic cells and prevent overgrowth of culture with macrophages, the bone marrow suspension was depleted using magnetic cell sorting with biotin-labeled cocktails of lineage-specific antibodies. For immunodepletion, the cell pellet (B1 Â 10 7 cells) was resuspended with 40 ml of the MidiMACS buffer, then 10 ml of Biotin-Antibody Cocktail (CD5, CD45R, CD11b, Ly-6G, 7-4 and Ter-119) (Miltenyi Biotec) was added, followed by incubation on ice for 10-15 min. Afterwards, 30 ml more of the buffer was added before adding 20 ml of Anti-Biotin Microbeads (Miltenyi Biotec) and incubation was allowed on ice for 15 min. The cells were washed with the MidiMACS buffer and centrifuged. The cell pellet was resuspended with the MidiMACS buffer and applied to the MidiMACS magnetic field column system (Miltenyi Biotec). The MS columns were used for smaller cell numbers and the LS columns were used for larger amounts of cells. The eluted cells were collected after several washing steps. The collected cells were maintained in culture with mesenchymal stem cell growth media (MSCGM, Cambrex, Rockland, ME, USA) containing mesenchymal growth supplements (Cambrex) and L-glutamine at 37 1C in a humidified 5% CO 2 -95% air atmosphere and allowed to attach for 4 days. Nonadherent cells were removed by changing the culture medium every other day. Colonies appeared on day 4 as fibroblast-like cells, which were bipolar in morphology. When primary cultures were 80% confluent, the cells were trypsinized, washed twice with PBS, resuspended in complete MSCGM at a concentration of 10 4 cells per cm 2 and subcultured. The cells resulting from the initial replating were designated as first-passage cells and maintained in complete MSCGM.
Fluorescent-activated cell sorting analysis
Cells were grown until confluent, trypsinized and counted before assessment. For FACS analysis, B1 Â 10 6 MSCs were resuspended in 100 ml of FACS buffer containing 10% fetal bovine serum in PBS and incubated for 30 min at 4 1C with 2 ml FITC-conjugated antibodies against the surface markers: CD45, CD44, CD31, Ly-6A/E (Sca-1), CD11b, CD71 and CD90.1 (Thy-1.1) (BD Biosciences, San Jose, CA, USA) according to the manufacture's instructions. After incubation, the labeled cells were diluted with 3 ml of FACS buffer, pelleted and resuspended in 500 ml FACS buffer. Generally, B10 4 cells were analyzed per sample. Labeled cells were analyzed with BD FACSCalibur flow cytometer (BD Biosciences). For direct fluorescent analysis, a small aliquot of cells was deposited on the glass slides using cytospin and viewed using a fluorescence microscope. Several stable cell lines containing the integrated cassette expressing puromycin-resistant and neomycin-sensitive genes were generated by nucleofection of the pNeoS1Pur construct (2 mg per nucleofection) into MSC isolated from wild-type C57BL6 mice. The Amaxa MSC Nucleofection Kit (program, U-23) was used according to the manufacturer's instructions. The cells were split 1:10 into multiple 10 cm plates and grown in 2 mg ml À1 puromycin for 2 weeks 48 h after nucleofection. Individual puromycin-resistant colonies were selected using a cloning cylinder and grown into 12-well culture plate. Ten random clones were characterized at the DNA sequence level by Southern blot and RT-PCR analysis followed by DNA sequencing by automatic DNA sequencer (ABI 373A; Applied Biosystems, Foster City, CA, USA) using direct primers.
RNA isolation, RT-PCR analysis and sequencing
Total RNA was isolated using the Qiagen RNeasy Mini Kit. RT-PCR was conducted using Reverse-iT One-Step Kit (ABgene Inc., Rochester, NY, USA). For a standard reaction, 1 mg of total RNA was mixed together with 0.4 mM each of primers in a final volume of 50 ml. All primers used in the study are listed in Table 1 . The amplification cycles for PCR were 47 1C for 30 min, 94 1C for 2 min, followed by 35 cycles of 94 1C for 20 s, 57 1C for 30 s and 72 1C for 1 min; followed by an additional extension for 5 min at 72 1C. The amplified fragments were separated on 1.5% agarose gel in 1 Â TAE buffer at 100 V for 1 h and visualized with ethidium bromide staining. RT-PCR products were purified using Qiagen Purification Kit and subsequently subjected to a direct DNA sequencing.
Southern blot analysis
Cells were grown until confluent and then lysed with a buffer containing 100 mM Tris-HCl (pH 8.5), 5 mM EDTA, 200 mM NaCl, 0.2% SDS and 100 mg ml À1 proteinase K at 56 1C overnight. Genomic DNA was purified by phenol/ chloroform extraction followed by isopropanol precipitation. To measure the copy number of integrated gene, 10 mg of the genomic DNA was digested with HindIII. Southern analysis was performed by a standard procedure. 33 Digested DNA was electrophoresed through 0.7% agarose gel with subsequent depurination, denaturation and neutralization. Then, DNA was transferred onto Zeta Probe nitrocellulose membrane (Bio-Rad, Hercules, CA, USA), cross-linked and probed with 32 P-labeled DNA fragments (specific activity of 1 Â 10 6 c.p.m. per ml in the hybridization buffer) isolated from the pNeoS1Pur and pCUB-EGFP66 plasmids. Hybridization signal was detected by autoradiography at À80 1C.
Western blot analysis
Nuclear proteins were isolated using NE-PER Nuclear and Cytoplasmic Extraction kit (Pierce, Rockford, IL, USA). Proteins were separated by a 4-12% gradient SDSpolyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membrane followed by the western blot analysis using polyclonal anti-EGFP antibodies ((Invitrogen). Immunocomplexes were detected by using HRP-labeled anti-rabbit secondary antibodies (Promega, Madison, WI, USA) and visualized by using SuperSignal WestFemto substrates (Pierce) .
Chromosomal targeting
For chromosomal targeting, 5 Â 10 4 cells were seeded per well in a six-well plate, 16-18 h before transfection. Oligonucleotide (7.5 mg) was diluted with OptiMEM and preincubated with Lipofectamine 2000 according to the manufacturer's instructions. Preformed complexes were added directly to cells with 2 ml of complete growth medium. After 6 h, cells were fed with 2 ml of fresh medium and allowed to grow. When MSC-Puro r Neo s cells were used, selection with G418 (500 mg ml À1 ) was started 48 h after transfection and continued for 10 days. The total number of G418-resistant clones was counted. For further analysis, several clones were picked using a cloning cylinder, propagated and subjected to verification at the DNA sequence level by RT-PCR analysis followed by direct DNA sequencing and differentiation assays. When MSC-EGFP m cells from transgenic mice were used, the expression of wild-type EGFP was detected using fluorescence microscopy and EGFPpositive cells were counted. For further analysis, EGFPpositive cells were sorted by FACS, expanded and analyzed at the DNA sequence level and differentiation assays.
Differentiation assays
Before addition of inductive media, MSC cultures were grown to confluence after which the standard MSC medium was replaced with the inductive media. Osteogenic differentiation was induced by culturing cells with osteoinductive medium (Cambrex). The cells were treated with osteogenic supplements for up to 3 weeks with three medium changes a week. Cells were morphologically examined as well ALP activity and ECM calcification was assessed. Analysis of ALP activity was done using the ALP Semiquantitative Histochemical Diagnostic Kit (Sigma, St Louis, MO, USA). For matrix mineralization, 3-week osteogenic cultures were fixed with 100% methanol and analyzed using 0.5% Alizarin red S in 0.1 M borate buffer (w/v, pH 4.0) as a staining solution. Cultures were also analyzed for mRNA transcripts of Cbfa1, an essential gene of skeletal development and postnatal bone formation and ALP and OCN, markers of a mature osteoblast. Total RNA was isolated and subjected for RT-PCR amplification using gene-specific primers listed in Table 1 .
To induce adipocytic differentiation, cells were cultured in adipogenic induction medium (Cambrex) for 2 weeks with a medium change every other day. For Table 1 .
Chondrogenic differentiation was performed using the micromass culture technique. Briefly, 10 ml of a concentrated cell suspension, 8 Â 10 6 cells per ml were plated into center of each well of six-well plate and allowed to attach at 37 1C for 2 h. Chondrogenic medium (Cambrex) was gently overlaid so as not to detach the cells nodules, and cultures were maintained in chondrogenic medium for up to 3 weeks with two medium changes a week, with transforming growth factor-b1 added freshly at each medium exchange. Sulfated protoglycans were specifically detected using Alcian blue staining under acidic conditions. Briefly, cell nodules were fixed with 4% paraformaldehyde for 15 min and washed extensively with PBS. Then fixed cells were incubated for 30 min with 1% (w/v) Alcian blue (Sigma) in 0.1 M HCl at pH 1.0 and washed with 0.1 M for 5 min to remove excess stain. Chondrogenic cultures were also analyzed for mRNA transcripts of Sox9, collagen type II, collagen type IX, Acan. The gene-specific primers are listed in Table 1 .
Transplantation of MSCs into transgenic mice and histological analysis
All animal procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals (National Institute of Health publication no. 86-23) and approved by the Animal Care Committee of the Thomas Jefferson University. Prior to transplantation, genetically corrected MSC-EGFP + cells were labeled with 1 mg ml
À1
CellTracker FM-DiI (Molecular Probes, Eugene, OR, USA) in suspension according to the manufacturer's instructions. Five transgenic CUBeGFP/Y66S mice received FM-DiI-MSC-EGFP + cells (1-2 Â 10 6 cells in 200-250 ml PBS per mouse) through the lateral tail vein. For intradermal injections, 5 Â 10 5 cells in 50 ml PBS were injected into dorsal skin depilated prior to transplantation. Assessments of transplantation were done 3 weeks after injection in accordance with the intensity and distribution of the positive signals. For analysis, transplanted mice were euthanized by CO 2 inhalation and samples were collected from bone marrow, spleen, liver, kidney, lungs, heart, skeletal muscles and skin. For histological analysis, collected tissue samples were embedded into OCT compound (VWR, Pittsburgh, PA, USA), frozen and cryosections were taken at a thickness of 10 mm. Before viewing, sections were fixed with 10% formalin at 37 1C for 20 min and stained with 46-diamidino-2-phenyl indole (DAPI; Sigma) to counterstain nuclei. All samples were evaluated for the presence of engrafted FM-DiI-MSC-EGFP + -expressing cells using fluorescence microscopy.
